

JENKINS | patent attorneys WILSON

RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

E. ERIC MILLS

BENTLEY I. OLIVE

MICHAEL J. CROWLEY

*CHRIS PERKINS, PH.D.

"JAMES DALY IV, PH.D.

JEFFREY CHILDERS, PH.D.

OF COUNSEL SOROJINI BISWAS

LICENSED ONLY IN CA

"LICENSED ONLÝ IN KY

May 23, 2005



"Express Mail" mailing number.:

Date of Deposit: May 23, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application Serial No. 08/999,690 for

VECTORS CARRYING THERAPEUTIC GENES ENCODING

ANTIMICROBIAL PEPTIDES FOR GENES THERAPY

Our Ref. No. 1406/205

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

- Information Disclosure Statement (2 pages); 1.
- 2. Form PTO-1449 (7 pages) in duplicate;
- Cited references (83 references) in computer readable form (in 3. duplicate);
- Statement That Computer Readable Copies are the Same (1 page); and 4.
- A return-receipt postcard to be returned to us with the U.S. Patent and 5. Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.

Registration No. 39,395

AAT/JD/cab Enclosures

Customer No: 25297

Gristi A. Butner

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Günzberg et al.

Group Art Unit: 1632

Serial No.: 08/999,690

Examiner: Li, Qian Janice

Filed: September 8, 1997

Docket No.: 1406/205

Confirmation No.: 4218

For: VECTORS CARRYING THERAPEUTIC GENES ENCODING ANTIMICROBIAL

PEPTIDES FOR GENE THERAPY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Appln. Serial No.: 08/999,690

Applicants submitted a Request for Continued Examination on May 9, 2005 and in accordance with 37 C.F.R. § 1.97 (b)(4) it is believed that no fee is due. However, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. **50-0426**.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.

Registration No. 39,395

1406/205

AAT/JD/cab

Enclosures

Customer No: 25297

FORM PTO-1449 U.S. Department of Commerce				Application No.:	08/999,690		
Patent and Trademark Office				Filing Date:	September 8, 1997		
List of pagents Cited by Applicant				First Named Günzburg et al. Inventor:			
	1				Group:	1632	
MAY 2	3 2005				Examiner:	Li, Qian Janice	
E .	, cer	·			Attorney Docket No.:	1406/205	-
RADE	MAY		U.	S. PATENT DOC	CUMENTS		
Examiner Initial			blication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear		
	1.	5,863,904	01/26/	1999	Nabel et al.		
	1		FOR	EIGN PATENT D	OCUMENTS	1	
Examiner Initials	Cite No.	Document Num (country code, no., k (if known)		Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	1
	2.	WO 95/00178		01/05/1995			-
	3.	WO 94/29437		12/22/1994			<u> </u>
	4.	WO 95/13375		05/18/1995			
	5.	WO 95/06415		03/09/1995			
	6.	WO 93/12251		06/24/1993			
	7.	WO 89/11539		11/30/1989			
	8.	WO 96/37623		11/28/1996			-
	9.	EP 0415731 A2		03/06/1991			
2,				OTHER DOCUM	MENTS		
Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journa			ıl, Date, Pertinent Pages, Etc	.	1
	10.				est Immune Response , Vol. 1 (No. 1) ; 32-34		
	11.	Terminal Repea	t Produc	t. Evidence for	f the Mouse Mammar the Molecular Structu munology, Vol. 22; 87	re of an Endogenous	

	12.	SALMONS et al., "Production of Mouse Mammary Tumor Virus upon Transfection of a Recombinant Proviral DNA into Cultured Cells", <u>Virology</u> , Vol. 144 , 101-114, 1985.	
	13.	KORMAN et al., "The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes a Type II Transmembrane Glycoprotein", <u>The EMBO Journal</u> , Vol. 11 (No. 5) ; 1901-1905, 1992.	
	14.	HORNSBY et al., "A Modified Procedure for Replica Plating of Mammalian Cells Allowing Selection of Clones Based on Gene Expression", BioTechniques, Vol. 12 (No. 2); 244-251, 1992.	
	15.	GÜNZBURG et al., "Factors Controlling the Expression of Mouse Mammary Tumour Virus", <u>Biochemical Journal</u> , Vol. 283 ; 625-632, 1992.	7
	16.	HUBER, Brigitte T., "Mls Genes and Self-Superantigens", <u>TIG</u> , Vol. 8 (No. 11) ; 399-402, November 1992.	
٠.	17.	SALMONS et al., "Current Perspectives in the Biology of Mouse Mammary Tumour Virus", Virus Research, Vol. 8; 81-102, 1987.	
r	18.	WINTERSPERGER, et al., "Negative-acting Factor and Superantigen Are Separable Activities of the Mouse Mammary Tumor Virus Long Terminal Repeat", Proceedings of the National Academy of Sciences; Vol. 92; 2745-2749, March 1995.	
	19.	DONEHOWER et al., "Regulatory and Coding Potential of the Mouse Mammary Tumor Virus Long Terminal Redundancy", <u>Journal of Virology</u> , Vol. 37 (No. 1) ; 226-238, January 1981.	-
	20.	VILE et al., "In Vitro and In Vivo Targeting of Gene Expression to Melanoma Cells", Cancer Research, Vol. 53 (No. 5); 962-967 (abstract only), 1993.	
	21.	CHOI et al., "A Superantigen Encoded in the Open Reading Frame of the 3' Long Terminal Repeat of Mouse Mammary Tumour Virus", Nature, Vol. 350; 203-207, March 1991.	
	22.	BRANDT-CARLSON et al., "Detection and Characterization of a Glycoprotein Encoded by the Mouse Mammary Tumor Virus Long Terminal Repeat Gene", Journal of Virology, Vol. 65 (No. 11); 6051-6060, November 1991.	
	23.	ACHA-ORBEA et al., "Clonal Deletion of V β14-bearing T Cells In Mice Transgenic for Mammary Tumour Virus", Nature, Vol. 350; 207-211, March 1991.	
	24.	BRANDT-CARLSON et al., "Phylogenetic and Structural Analyses of MMTV LTR ORF Sequences of Exogenous and Endogenous Origins", Virology, Vol. 193; 171-185, 1993.	. :

,			
2	25.	KRUMMENACHER et al., "The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes A 47 kDa Glycoprotein With A Short Half-life In Mammalian Cells", Molecular Immunology, Vol. 30 (No. 13); 1151-1157, 1993.	
2	26.	WINSLOW et al., "Detection and Biochemical Characterization of the Mouse Mammary Tumor Virus 7 Superantigen (Mls-1 ^a)", Cell, Vol. 71; 719-730, November 1992.	
2	27.	WINSLOW et al., "Processing and Major Histocompatibility Complex Binding of the MTV7 Superantigen", Immunity, Vol. 1; 23-33, April 1994.	•
2	28.	KAY et al., "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-deficient Dogs", <u>Science</u> , Vol. 262 (No. 5130) ; 117-119, October 1993.	
2	29.	PULLEN et al., "The Open Reading Frames in the 3' Long Terminal Repeats of Several Mouse Mammary Tumor Virus Integrants Encode Vβ3-specific Superantigens", Journal of Experimental Medicine, Vol. 175; 41-17, January 1992.	
. 3	30.	MOHAN et al., "Production and Characterization of an Mls-1-specific Monoclonal Antibody", <u>Journal of Experimental Medicine</u> , Vol. 177 ; 351-358, February 1993.	-
, 3	31.	Genbank® Accession No. J02255	
3	32.	Genbank® Accession No. M28246	
3	33.	Genbank® Accession No. M28247	
3	34.	Genbank® Accession No. M28248	
3	35.	Definition of antisense DNA from <u>Stedman's Medical Dictionary</u>	
3	36.	SCOTT et al., "Promoter-Proximal Poly (A) Sites Are Processed Efficiently, but the RNA Products Are Unstable in the Nucleus", Molecular and Cellular Biology, Vol. 17 (No. 4); 2127-2135, April 1997.	
3	37.	FAUSTINELLA et al., "A New Family of Murine Retroviral Vectors with Extended Multiple Cloning Sites for Gene Insertion", <u>Human Gene Therapy</u> , Vol. 5 ; 307-312, 1994.	
3	38.	MEHIGH et al., "Development of a Recombinant Bovine Leukemia Virus Vector for Delivery of a Synthetic Bovine Growth Hormone-Releasing Factor Gene into Bovine Cells", <u>Journal of Animal Science</u> , Vol. 71 ; 687-693, 1993.	ĸ.
3	39.	MEE et al., "Construction and Hormone Regulation of A Novel Retroviral Vector", Gene, Vol. 88; 289-292, 1990.	
4	10.	PANGANIBAN et al., "The Retrovirus <i>pol</i> Gene Encodes A Product Required for DNA Integration: Identification of A Retrovirus <i>int</i> locus", <u>Proceedings from the National Academy of Sciences</u> , Vol. 81 ; 7885-7889, December 1984.	
I			_

4	1. LONGMORE et al., "Both Megakaryocytopoiesis and Erythropoiesis Are Induced in Mice Infected With a Retrovirus Expressing an Oncogenic Erythropoietin Receptor", Blood, Vol. 82 (No. 8); 2386-2395, October 1993.
4:	2. PANGANIBAN et al., "The Terminal Nucleotides of Retrovirus DNA Are Required for Integration But Not Virus Production", Nature, Vol. 306; 155-160, November 1983.
4:	SCARPA et al., "Characterization of Recombinant Helper Retroviruses from Moloney-Based Vectors in Ecotropic and Amphotropic Packaging Cell Lines", Virology, Vol. 180; 849-852, 1991.
4.	FELDER et al., "Functional and Biological Properties of an Avian Variant Long Terminal Repeat Containing Multiple A to G Conversions in the U3 Sequence", Journal of Virology, Vol. 68 (No. 8); 4759-4767, August 1994.
4	5. HARPER et al., "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases", Cell, Vol. 75; 805-816, November 1993.
. 40	6. MILLER et al., "Improved Retroviral Vectors for Gene Transfer and Expression", BioTechniques, Vol. 7 (No. 9); 980-990, 1989.
, 4	PRICE et al., "Lineage Analysis in The Vertebrate Nervous System by Retrovirus-mediated Gene Transfer", <u>Proceedings from the National Academy of Sciences</u> , Vol. 84 ; 156-160, January 1987.
48	3. FELDMAN et al., "Prevention of Restenosis After Coronary Angioplasty: Towards a Molecular Approach", Fundamental & Clinical Pharmacology, Vol. 9; 8-16, 1995.
49	O. CRYSTAL, Ronald F., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", Science, Vol. 270; 404-410, 1995.
50	TSANG et al., "Induction of Human Cytotoxic T Cell Lines Directed Against Point-Mutated p21 Ras-Derived Synthetic Peptides", <u>Vaccine Research</u> , Vol. 3 (No. 4) ; 183-193, 1994.
5	HÄRTIG et al., "Regulation of Expression of Mouse Mammary Tumor Virus Through Sequences Located in the Hormone Response Element: Involvement of Cell-Cell Contact and a Negative Regulatory Factor", <u>Journal of Virology</u> , Vol. 67 (No. 2) ; 813-821, February 1993.
52	NAKANISHI et al., "Identification of the Active Region of the DNA Synthesis Inhibitory Gene p21 ^{Sdi1,CIP1/WAF1} " <u>The EMBO Journal</u> , Vol. 14 (No. 3) ; 555-563, 1995.
50	NODA et al., "Cloning of Senescent Cell-Derived Inhibitors of DNA Synthesis Using an Expression Screen", Experimental Cell Research, Vol. 211; 90-98, 1994.
54	STANGE et al., "Prolonged Biochemical and Morphological Stability of Encapsulated Liver Cells - A New Method", <u>Biomaterials, Artificial Cells and Immobilization Biotechnology</u> , Vol. 21 (No. 3) ; 343-352, 1993.

55.	KATAYOSE et al., "Consequences of p53 Gene Expression By Adenovirus Vector On Cell Cycle Arrest and Apoptosis In Human Aortic Vascular Smooth Muscle Cells", <u>Biochemical And Biophysical Research Communications</u> , Vol. 215 (No. 2) ; 446-451, October 1995.	
56.	BOND et al., "Mutant p53 Rescues Human Diploid Cells from Senescence Without Inhibiting the Induction of SD11/WAF1", <u>Cancer Research</u> , Vol. 55 ; 2404-2409, June 1995.	
57.	SKOTZKO et al., "Retroviral Vector-mediated Gene Transfer of Antisense Cyclin G1 (CYCG1) Inhibits Proliferation of Human Osteogenic Sarcoma Cells", <u>Cancer Research</u> , Vol. 55 ; 5493-5498, December 1995.	
58.	NAKANISHI et al., "Exit From G ₀ and Entry Into the Cell Cycle of Cells Expressing p21 ^{Sdi1} Antisense RNA", <u>Proceedings from the National Academy of Sciences</u> , Vol. 92 ; 4352-4356, May 1995.	
59.	ZAKUT et al., "The Tumor Suppression Function of p21 ^{Waf} ('half-WAF')", <u>Oncogene</u> , Vol. 11 ; 393-395, 1995.	
60.	JOHNSON et al., "Evidence for a p53-Independent Pathway for Upregulation of SDI1/CIP1/WAF1/p21 RNA in Human Cells", Molecular Carcinogenesis, Vol. 11; 59-64, 1994.	
61.	RUBELJ et al., "SV40-Transformed Human Cells in Crisis Exhibit Changes That Occur in Normal Cellular Senescence", <u>Experimental Cell Research</u> , Vol. 211 ; 82-89, 1994.	
62.	XIONG et al., "p21 Is a Universal Inhibitor of Cyclin Kinases", Nature, Vol. 366; 701-704, December 1993.	
63.	GÜNZBURG et al., "A Mammary-Specific Promoter Directs Expression of Growth Hormone not only to the Mammary Gland, but also to Bergman Glia Cells in Transgenic Mice", Molecular Endocrinology, Vol. 5 (No. 1); 123-133, 1991.	
64.	HUNTER, Tony, "Braking the Cycle", Cell, Vol. 75, 839-841, December 1993.	
65.	EL-DEIRY et al., "WAF1, a Potential Mediator of p53 Tumor Suppression", Cell, Vol. 75; 817-825, November 1993.	
66.	JUNKER et al., "Genetic Instability of a MoMLV-based Antisense Double-copy Retroviral Vector Designed for HIV-1 Gene Therapy", Gene Therapy, Vol. 2; 639-646, 1995.	
67.	GÜNZBURG et al., "Retroviral Vectors Directed to Predefined Cell Types for Gene Therapy", <u>Biologicals</u> , Vol. 23 ; 5-12, 1995.	
68.	COUTURE et al., "Retroviral Vectors Containing Chimeric Promoter/Enhancer Elements Exhibit Cell-Type-Specific Gene Expression", Human Gene Therapy, Vol 5; 667-677, 1994.	

82.	KAPLITT et al., "Genetic Modification of Cells with Retrovirus Vectors", <u>Viral Vectors</u> , M.G. Kaplitt et al., eds. (San Diego, CA: Academic Press, Inc.); 215-216 and 299, 1995.	
81.	JANE et al., "Vector Development: A Major Obstacle in Human Gene Therapy", Annals of Medicine, Vol. 30 (No. 5); 413-415, October 1998.	
80.	WINTERSPERGER et al., "Superantigen and NAF Activities of Mouse Mammary Tumour Virus Can Be Separated", <u>Journal of Cellular Biochemistry</u> , Supplemental 17D:54, March 1993.	
79.	Genbank® Accession No. V01175	
78.	WINTERSPERGER et al., "A Transient Assay for Gene Expression Studies in B Lymphocytes and It's use for Superantigen Assays", <u>BioTechniques</u> , Vol. 16 (No. 5) , 882-886, 1994.	
 77.	FASEL et al., "The Region of Mouse Mammary Tumor Virus DNA Containing the Long Terminal Repeat Includes a Long Coding Sequence and Signals for Hormonally Regulated Transcription", <u>The EMBO Journal</u> , Vol. 1 (No. 1) ; 3-7, 1982.	
 76.	Definition of "Provirus" from <u>Dorland's Illustrated Medical Dictionary</u> , 28 th Edition, W.B. Saunders Co., 1373, 1994.	
75.	SALMONS et al., "naf, a trans-Regulating Negative-Acting Factor Encoded Within the Mouse Mammary Tumor Virus Open Reading Frame Region", <u>Journal of Virology</u> , Vol. 64 (No. 12) ; 6355-6359, December 1990.	
 74.	GÜNZBURG et al., "Endogenous Superantigen Expression Controlled by a Novel Promoter in the MMTV Long Terminal Repeat", <u>Nature</u> , Vol. 364 ; 154-158, July 1993.	
73.	VILE et al., "Tissue-Specific Gene Expression from Mo-MLV Retroviral Vectors with Hybrid LTRs Containing the Murine Tyrosinase Enhancer/Promoter", <u>Virology</u> , Vol. 214 ; 307-313, 1995.	
72.	FERRARI et al., "A Retroviral Vector Containing a Muscle-Specific Enhancer Drives Gene Expression Only in Differentiated Muscle Fibers", <u>Human Gene Therapy</u> , Vol. 6 ; 733-742, June 1995.	
 71.	ROBINSON et al., "Retroviral Vector With a CMV-IE/HIV-TAR Hybrid LTR Gives High Basal Expression Levels and Is UP-Regulated by HIV-1 Tat", Gene Therapy, Vol. 2; 269-278, 1995.	
70.	CANNON et at., "Murine Leukemia Virus-Based Tat-Inducible Long Terminal Repeat Replacement Vectors: a New System for Anti-Human Immunodeficiency Virus Gene Therapy", <u>Journal of Virology</u> , Vol. 70 (No. 11) ; 8234-8240, November 1996.	
69.	SALMONS et al., "Targeting of Retroviral Vectors for Gene Therapy", Human Gene Therapy, Vol. 4; 129-141, 1993.	

	83.	GUNTAKA, Ramareddy V., "Transcription Termination and Polyadenylation in Retroviruses", Microbiological Reviews, Vol. 57 (No. 3); 511-521, September 1993.	2 d d d d d d d d d d d d d d d d d d d
EXAMINER		DATE CONSIDERED	

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.